Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study on the Efficacy and Safety of Stereotactic Ablative Body Radiotherapy Combined with Axitinib and Toripalimab in Recurrent or Metastatic Renal Cell Carcinoma

NCT06889649 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT06889649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06889649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study on the Efficacy and Safety of Stereotactic Ablative Body Radiotherapy Combined with Axitinib and Toripalimab in Recurrent or Metastatic Renal Cell Carcinoma
Lead sponsor
Peking University First Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2019
Completion date
February 20, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, radiation therapy, renal cancer metastatic, targeted therapy